BPS Bioscience Inc.
中级会员 | 第3年

当前位置:BPS Bioscience Inc.>>CAR T-Cell Therapy Cell Lines>> 79853Anti-CD19 CAR / NFAT (Luciferase) Reporter Jurkat Cell Line (CD19 SCFV-CD28-4-1BB-CD3ζ)

Anti-CD19 CAR / NFAT (Luciferase) Reporter Jurkat Cell Line (CD19 SCFV-CD28-4-1BB-CD3ζ)

参  考  价面议
具体成交价以合同协议为准

产品型号79853

品       牌BPS Bioscience

厂商性质生产商

所  在  地

更新时间:2023-11-11 20:53:59浏览次数:325次

联系我时,请告知来自 化工仪器网
同类优质产品更多>
●Purchase●DescriptionAnti-CD19CAR/NFAT(Luciferase)ReporterJurkatCellLine(CD19SCFV-CD28-4-1BB-CD3ζ)isastablecelllineexpressingananti-CD19CARandanNFAT-dependentluciferasereporter
Purchase
Description

Anti-CD19 CAR/NFAT (Luciferase) Reporter Jurkat Cell Line (CD19 SCFV-CD28-4-1BB-CD3ζ) is a stable cell line expressing an anti-CD19 CAR and an NFAT-dependent luciferase reporter. The reporter cell line has been validated for anti- CD19 expression by flow cytometry, and for luciferase reporter activation by target cells, including the CD19 CHO cell line. Anti-CD19 CAR consists of the anti-CD19 scFv linked to 3rd generation CAR containing the CD28, 4-1BB co-stimulatory domains and the CD3ζ signaling domain.

The cell line can be used for primary screening and functional validation of anti-CD19 CAR construct and lentivirus before testing is performed in primary T cells.

Figure 1: Lenti-vector used to generate anti-CD19 CAR lentivirus.

Figure 2. Schematic of anti-CD19 CAR.
Anti-CD19 (scFv) is linked to the 3rd generation CAR with CD28 transmembrane and costimulatory domains, 4-1BB, and CD3ζ components.

Purchase of this cell line is for research purposes only; commercial use requires a separate license. View the full terms and conditions.

会员登录

×

请输入账号

请输入密码

=

请输验证码

收藏该商铺

X
该信息已收藏!
标签:
保存成功

(空格分隔,最多3个,单个标签最多10个字符)

常用:

提示

X
您的留言已提交成功!我们将在第一时间回复您~
拨打电话
在线留言